Srilatha Edupuganti

发表

The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response1

C. Rice, J. Altman, R. Ahmed, 2009, The Journal of Immunology.

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

J. Altman, S. Staprans, M. Feinberg, 2008, Immunity.

Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination

Rustom Antia, Helder I. Nakaya, Bali Pulendran, 2015, Proceedings of the National Academy of Sciences.

A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.

M. Cetron, A. Barrett, R. Lanciotti, 2013, The American journal of tropical medicine and hygiene.

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial

R. Koup, D. Bernstein, Shital M. Patel, 2015, PloS one.

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans

Carl W Davis, Christopher Chiu, Adolfo García-Sastre, 2014, Proceedings of the National Academy of Sciences.

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Madeleine K. D. Scott, B. Pulendran, P. Khatri, 2020, Science.

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Vineet D. Menachery, S. Stowell, J. Guarner, 2020, Cell Reports Medicine.

Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus

J. Wrammert, R. Ahmed, M. Mulligan, 2016, Proceedings of the National Academy of Sciences.

Homologous and Heterologous Covid-19 Booster Vaccinations

D. Montefiori, R. Coler, P. Roberts, 2022, The New England journal of medicine.

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

J. Yewdell, C. del Rio, A. Mehta, 2011, The Journal of experimental medicine.

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

Johannes B. Goll, S. El-Kamary, M. Mulligan, 2015, Vaccine.

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial

D. Bernstein, M. Mulligan, N. Rouphael, 2014, Open forum infectious diseases.

Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas.

C. del Rio, C. Franco-Paredes, S. Edupuganti, 2009, Journal of travel medicine.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

J. Kublin, J. Fuchs, N. Sardesai, 2013, The Journal of infectious diseases.

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

J. Yewdell, C. del Rio, A. Mehta, 2011, The Journal of Experimental Medicine.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Capsule switching of Neisseria meningitidis.

P. Cieslak, D. Stephens, S. Edupuganti, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.

M. Mulligan, N. Rouphael, S. Edupuganti, 2012, The Lancet. Infectious diseases.

Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure

M. Mulligan, K. Ault, N. Rouphael, 2020, Vaccines.

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

Tianwei Yu, Mark R Prausnitz, Sebastien Henry, 2017, The Lancet.

COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva

O. Laeyendecker, S. Klein, M. Betenbaugh, 2020, Journal of Clinical Microbiology.

Homologous and Heterologous Covid-19 Booster Vaccinations

D. Montefiori, R. Coler, P. Roberts, 2022, New England Journal of Medicine.

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Diane J Post, D. Montefiori, D. Szydlo, 2022, Cell Reports Medicine.

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

A. Sette, R. Baric, D. Margolis, 2020, Science Immunology.

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

A. Mehta, M. McElrath, J. Wrammert, 2021, medRxiv.

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

Mark Mulligan, Christopher Chiu, Jonathan W. Yewdell, 2012, Proceedings of the National Academy of Sciences.

Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood

M. Mulligan, W. Keitel, Shital M. Patel, 2018, Open forum infectious diseases.

Innate, T-, and B-Cell Responses in Acute Human Zika Patients

M. Mulligan, Shital M. Patel, K. Murray, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Characterization of the Gene Cassette Required for Biosynthesis of the (α1→6)-LinkedN-Acetyl-d-Mannosamine-1-Phosphate Capsule of Serogroup A Neisseria meningitidis

D. Stephens, S. Edupuganti, Srilatha Edupuganti, 1998, Journal of bacteriology.

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

A. Mehta, M. McElrath, J. Wrammert, 2021, Cell Reports Medicine.

Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain

Vineet D. Menachery, J. Wrammert, R. Ahmed, 2021, The Journal of Immunology.

Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood

W. Bellini, J. Wrammert, R. Ahmed, 2019, Proceedings of the National Academy of Sciences.

A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses

N. Rouphael, L. Wells, K. Moremen, 2021, medRxiv.

Pericarditis Associated With Acute Zika Virus Infection in a Returning Traveler

M. Mulligan, Shital M. Patel, N. Rouphael, 2017, Open forum infectious diseases.

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

Margaret A. Johns, M. Dhodapkar, S. Ramalingam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.

C. Woods, M. Mulligan, K. Edwards, 2014, JAMA.

Origin and differentiation of human memory CD8 T cells after vaccination

G. Alexe, W. Greenleaf, M. McElrath, 2017, Nature.

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.

D. Bernstein, M. Mulligan, D. Ince, 2014, JAMA.

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

D. Mehrotra, M. Mulligan, J. Shiver, 2009, AIDS research and human retroviruses.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report

D. Montefiori, D. Szydlo, P. Roberts, 2021, medRxiv.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Allan C. deCamp, J. Kublin, J. Mascola, 2017, Statistical communications in infectious diseases.

The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD 8 T Cell Response 1

C. Rice, J. Altman, C. del Rio, 2009 .

T Cell Response + CD8Broad and Polyfunctional Human Memory The Yellow Fever Virus Vaccine Induces a

J. Altman, Rama S. Akondy, D. Teuwen, 2009 .

This information is current as T Cell Response + CD 8 Broad and Polyfunctional Human Memory The Yellow Fever Virus Vaccine Induces a

J. Altman, Rama S. Akondy, D. Teuwen, 2009 .

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Johannes B. Goll, S. El-Kamary, M. Mulligan, 2017, Vaccine.

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.

J. Mascola, C. Andrews, J. Ledgerwood, 2022, The Lancet. Infectious diseases.

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women

J. Baeten, S. Delany-Moretlwe, H. Rees, 2023, Journal of the International AIDS Society.

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Allan C. deCamp, J. Mullins, J. Kublin, 2021, The New England journal of medicine.

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

J. Kublin, D. Montefiori, H. Schuitemaker, 2020, The lancet. HIV.

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

J. Kublin, D. Montefiori, H. Schuitemaker, 2022, The Journal of infectious diseases.

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens

Lindsay N. Carpp, S. Buchbinder, M. McElrath, 2022, EBioMedicine.

Robust antibody and cellular responses induced by DNA-only vaccination for HIV.

N. Sardesai, D. Weiner, Jian Yan, 2020, JCI insight.

Risk of COVID-19 after natural infection or vaccination

Nicole L. Nollen, Eric A. Meyerowitz, Waseem M. Chughtai, 2023, EBioMedicine.